Analysts Offer Predictions for Globus Medical Q3 Earnings

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research increased their Q3 2025 EPS estimates for Globus Medical in a research note issued to investors on Thursday, December 12th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings of $0.84 per share for the quarter, up from their prior forecast of $0.83. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2026 earnings at $0.98 EPS.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.18. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The business had revenue of $625.71 million for the quarter, compared to analysts’ expectations of $604.69 million. During the same quarter in the prior year, the company earned $0.57 earnings per share. The business’s quarterly revenue was up 63.1% on a year-over-year basis.

A number of other analysts have also recently weighed in on the company. Bank of America increased their price objective on Globus Medical from $55.00 to $80.00 and gave the stock an “underperform” rating in a research report on Wednesday, November 6th. BTIG Research boosted their price objective on shares of Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. StockNews.com lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Piper Sandler raised their price objective on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus boosted their target price on Globus Medical from $80.00 to $92.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $92.18.

Globus Medical Trading Down 0.9 %

Shares of GMED opened at $81.70 on Monday. The firm has a market cap of $11.12 billion, a PE ratio of 121.94, a price-to-earnings-growth ratio of 1.99 and a beta of 1.19. The company’s 50 day simple moving average is $79.05 and its 200-day simple moving average is $72.99. Globus Medical has a 12-month low of $49.14 and a 12-month high of $87.22.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. V Square Quantitative Management LLC purchased a new position in Globus Medical in the 3rd quarter worth approximately $27,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Globus Medical during the second quarter valued at about $33,000. Quarry LP boosted its holdings in shares of Globus Medical by 698.4% in the 3rd quarter. Quarry LP now owns 495 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 433 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Globus Medical by 230.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock valued at $39,000 after purchasing an additional 385 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in Globus Medical in the 2nd quarter worth about $52,000. Institutional investors own 95.16% of the company’s stock.

Insider Activity at Globus Medical

In related news, CEO Daniel T. Scavilla sold 60,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total value of $4,801,200.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Kelly Huller sold 2,500 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total value of $217,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 97,500 shares of company stock worth $7,674,950. 18.54% of the stock is owned by insiders.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.